Compare SMX Security Matters plc (SMX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs State Street SPDR S&P Biotech ETF — how do they compare? SMX Security Matters plc trades at $16.48 (market cap $17.04M), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| SMX | XBI | |
|---|---|---|
Market Cap | $17.04M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $103.71K | $164.28 |
52-Week Low | $12.87 | $86.92 |
Enterprise Value | -$14.29M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX (Security Matters) trades at $16.16, up 2.28% on the day, but technical indicators signal a bearish trend with the stock near its pivot point. The company reported a net loss of $169.18M for 2025, with negative profitability metrics (ROE -819.22%), though recent news highlights a strengthened balance sheet and progress in commercializing its materials traceability platform amid growing regulatory demand for recycled plastics.
The outlook remains high-risk given persistent losses and cash burn, offset by potential from regulatory tailwinds in recycling. Investors face significant execution risk, but the company's niche in material verification could capture value if commercialization accelerates. The stock's viability hinges on reversing operational losses and achieving sustainable revenue growth.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
